CTEC: Convatec Group PLC - Summary | Jitta

Convatec Group PLC

LON:CTEC

Price
£2.00
Loss Chance
42.4%
6.81JITTA SCORE
40.95%Over Jitta Line
Jitta Ranking
232 / 877
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (62)
Recent Business Performance (69)
Financial Strength (59)
Return to Shareholders (61)
Competitive Advantage (68)
Jitta Signs
Revenue and EarningConsistent
Operating MarginExpansion
Dividend PayoutIncreasing Every Year
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
6.81
40.95%
3.28
141.83%
Health Care Supplies
1.96
100.00%
6.40
1.63%
2.73
90.29%
COMPANY DESCRIPTION
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson’s disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.